Gabriel Gabriel, Griffiths Kalinda, Descallar Joseph, Yap Mei Ling, Vinod Shalini, Shafiq Jesmin, Jacob Susannah, Barton Michael, Mcerlean Gemma, Anderson Susan, Sheehan David, Delaney Geoff
Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital, Liverpool, New South Wales, Australia.
South-Western Sydney Clinical Campus, University of New South Wales Medicine & Health, Sydney, New South Wales, Australia.
J Med Imaging Radiat Oncol. 2025 Jun;69(4):509-523. doi: 10.1111/1754-9485.13851. Epub 2025 Apr 10.
Aboriginal patients face barriers to accessing cancer care. Few studies have evaluated the utilisation of radiotherapy or surgery in Aboriginal people. This study aims at assessing variation in types of cancer, degree of spread (DOS) at presentation, utilisation rates of cancer surgery and radiotherapy between Aboriginal and non-Aboriginal cancer patients.
Retrospective analysis of de-identified linked datasets. All patients with registered notifiable cancer in the NSW cancer registry 2009-2018 separated by Aboriginality status were included.
Totally 389,992 people were diagnosed in NSW during study period; 8970 people (2.3%) identified as Aboriginal. In univariate analysis, Aboriginal people presented at diagnosis with statistically significant younger age, greater comorbidity, advanced (DOS) and greater proportions living in most disadvantaged areas than non-Aboriginal people. Based on univariate analysis, Aboriginal patients received radiotherapy more frequently than non-Aboriginal patients (30.3% versus 26.0%, p < 0.01). Non-Aboriginal patients underwent cancer surgery more frequently than Aboriginal patients (57.0% versus 51.2%, p < 0.01). When stratified by tumour type and adjustment for patient and clinical factors, radiotherapy and surgery utilisation varied by type of cancer.
The degree of cancer spread, and the presence of comorbidities remains a greater issue for Aboriginal people. Access to radiotherapy increased significantly for Aboriginal patients during the past 10 years. However, differences in surgical and radiotherapy utilisation exist. These differences can be partially explained by the greater DOS and presence of comorbidity in Aboriginal patients leading to less surgical intervention and greater requirement for radiotherapy.
原住民患者在获得癌症治疗方面面临障碍。很少有研究评估原住民对放疗或手术的利用情况。本研究旨在评估原住民和非原住民癌症患者在癌症类型、就诊时的扩散程度(DOS)、癌症手术和放疗利用率方面的差异。
对去识别化的关联数据集进行回顾性分析。纳入了新南威尔士州癌症登记处2009 - 2018年登记的所有可报告癌症患者,并按原住民身份进行分类。
在研究期间,新南威尔士州共有389,992人被诊断患有癌症;其中8970人(2.3%)被认定为原住民。在单因素分析中,与非原住民相比,原住民在诊断时年龄更小、合并症更多、扩散程度(DOS)更高,且居住在最贫困地区的比例更大,差异具有统计学意义。基于单因素分析,原住民患者接受放疗的频率高于非原住民患者(30.3%对26.0%,p < 0.01)。非原住民患者接受癌症手术的频率高于原住民患者(57.0%对51.2%,p < 0.01)。按肿瘤类型分层并对患者和临床因素进行调整后,放疗和手术的利用率因癌症类型而异。
癌症扩散程度和合并症的存在对原住民来说仍然是更严重的问题。在过去10年中,原住民患者获得放疗的机会显著增加。然而,手术和放疗的利用率存在差异。这些差异部分可以解释为原住民患者的扩散程度更高且存在合并症,导致手术干预较少,对放疗的需求更大。